Research Results
Beta Version
Use the search bar below to find studies, or apply one or more filters to narrow your results. See our list of keywords to guide your search.
Search by keyword
Select
Select
- All Risk Factors
- Air Pollution
- Alcohol
- Antimicrobials
- Artificial sweeteners
- Bisphenols
- Body Weight
- Breast Density
- Chemical Mixtures
- Chemicals in products
- Cleaning Products
- Diet
- Exercise
- Family History
- Furniture & Electronics
- Genetics
- Gut Health
- Hair Dye
- Hormones
- Inflammation
- Job
- Light at night
- Metals
- Neighborhood
- Night Shift Work
- Noise
- Non-stick Pans & Waterproof Gear
- Oral Contraceptives
- PAHs
- Parabens
- PCBs
- Personal Care Products
- Pesticides
- PFAS
- Pharmaceuticals
- Place-based
- Plastic
- Pregnancy & Breastfeeding
- Processed Food
- Puberty Age
- Race/Ethnicity
- Radiation
- Red meat
- Scented Products & Soft Plastic
- Sleeping Patterns
- Soda
- Stress
- Sugar
- Sunscreen
- Tobacco
- Vitamin D
Select
Select
Select
Select
Select the Chemical Agents
- All Chemical Agents
- 1,1,2,2-TCA
- 1,3-Butadiene
- Acrolein
- Aldrin
- Alkylphenols
- Antimicrobials
- Antimicrobials: QACs, Triclosan, Triclocarban
- Aromatic Amines
- Arsenic
- Artificial Sweeteners
- Atrazine
- Benzene
- Bisphenols
- Cadmium
- Chlordane
- Chlorpyrifos
- DDT
- Dibutyl Phthalate
- Dichlorvos
- Dieldrin
- Dioxins
- ell/
- Ethanol (alcohol)
- Ethyl Benzene
- Ethylene Oxide
- Flame Retardants
- Food
- Formaldehyde
- Glyphosate
- Heptachlor
- Hormones
- Insulin
- Lead
- Light at Night
- Mercury
- Metals
- Methoxyclor
- Naphthalene
- Night Shift Work
- Nitrogen Dioxide
- Noise
- Oral Contraceptives
- Organochlorine Pesticides
- Organophosphate Pesticides
- Ozone
- PAHs
- Parabens
- Particulate Matter
- PCBs
- Pesticides
- PFAS
- Phenols
- Phthalates
- Processed Food
- PVC
- Radiation: Ionizing
- Radiation: Non-Ionizing
- Soda
- Stress
- Sugar
- Tobacco
- Toluene
- Trichloroethylene
- Triclosan
- Ultraviolet Radiation
- UV Filters
- Vinyl Chloride
Select the Study Tags
Sort By
- Relevance
- Title (A to Z)
- Title (Z to A)
- Publication Year (Ascending)
- Publication Year (Descending)
- Authors (A to Z)
- Authors (Z to A)
2025
Clin Transl Oncol
A review of 29 studies found that breast cancer patients have distinct imbalances in their gut and breast tissue bacteria that vary based on cancer type, stage, menopause status, body weight, and physical activity, though no single bacterial profile has yet emerged as a reliable biomarker. The research suggests that gut microbiome composition may influence how well breast cancer treatments work, with some beneficial bacteria and their metabolites potentially improving therapy effectiveness or slowing tumor growth. These findings highlight the microbiome as a promising new area for developing personalized breast cancer treatments and improving outcomes, though more research is needed to identify specific bacterial targets and understand the underlying mechanisms.
2025
Breast Cancer
A meta-analysis of 10 studies involving 1,730 women found that breast cancer patients had significantly lower gut bacterial diversity compared to healthy controls, with particularly pronounced differences in premenopausal women and women with normal body weight. The reduction in gut microbiome diversity—a marker of gut health—was not seen in overweight or obese women, suggesting body weight may influence the relationship between gut bacteria and breast cancer. These findings support the hypothesis that gut bacteria may play a role in breast cancer development, possibly through their influence on estrogen levels, though more research is needed to understand the underlying mechanisms and whether improving gut health could help prevent breast cancer.
2025
Sci Rep
A study of 50 breast cancer patients and 50 healthy women found that 60% of breast cancer patients had metabolic syndrome (a cluster of conditions including high blood pressure, blood sugar, and cholesterol) compared to 40% of healthy controls, and breast cancer patients had significantly lower levels of beneficial gut bacteria—specifically Lactobacillus and Bifidobacterium. These beneficial bacteria normally help protect against disease and regulate the immune system, suggesting their depletion may play a role in breast cancer development. The findings support a connection between metabolic health, gut bacteria composition, and breast cancer risk, pointing to potential new avenues for cancer prevention through dietary or probiotic interventions, though more research is needed.
2024
Cancer Epidemiol Biomarkers Prev
While breast tissue was once thought to be sterile, the past decade has revealed it harbors unique bacterial communities, with growing evidence that breast tumor tissue has different microbiome compositions compared to healthy breast tissue. However, despite numerous studies examining breast cancer patients, research has been inconsistent in methodology and sample sizes, making it difficult to identify specific bacterial patterns reliably associated with breast cancer risk or outcomes. Only one large prospective study has linked breast microbiome composition to cancer prognosis, highlighting the need for larger, long-term studies to determine whether the breast microbiome could serve as a tool for predicting breast cancer risk, progression, or treatment response.
2024
Thorac Cancer
A study combining genetic analysis and bacterial sequencing in East Asian women found that specific oral bacteria may causally influence breast cancer risk, with 30 tongue bacteria and 37 saliva bacteria showing significant associations. The research identified seven bacterial genera present in both tongue and saliva samples that appear to affect breast cancer risk, and found that breast cancer patients had higher levels of certain bacterial families (Pasteurellaceae and Streptococcaceae) but lower levels of others (Bacteroidaceae) compared to healthy women. These findings suggest that the composition of bacteria in the mouth may not just be associated with breast cancer but could actually play a causal role in disease development, though more research is needed to understand the underlying mechanisms.
2024
Heliyon
A mouse study found that ginger volatile oil (GVO) reduced triple-negative breast cancer tumor growth in animals exposed to bisphenol A (BPA), a common plastic chemical known to promote cancer, with the effect linked to restoration of healthy gut bacteria. BPA exposure disrupted the gut microbiome by reducing bacterial diversity and beneficial bacteria like Lactobacillus, but treatment with ginger oil reversed these changes and increased the ratio of beneficial bacteria while decreasing harmful bacteria. The findings suggest that ginger compounds may counteract BPA’s cancer-promoting effects through their impact on the gut microbiome, offering a potential dietary strategy to mitigate harm from plastic chemical exposure, though human studies are needed to confirm these results.
2024
Environ Int
A study in mice found that exposure to DEHP—a common chemical used to make plastics flexible—disrupts the gut-mammary connection, causing changes in gut bacteria, intestinal inflammation, and direct damage to mammary (breast) tissue that could impair milk production. DEHP altered gut microbiome composition (increasing some bacteria while decreasing others), changed blood metabolite levels, and its breakdown product (MEHP) triggered cell death in mammary tissue through multiple pathways. These findings raise concerns about DEHP exposure from plastics affecting both human breast health and dairy production in livestock, while identifying potential therapeutic targets to counteract the chemical’s harmful effects on the gut-breast axis.
2024
Int J Mol Sci
This comprehensive review covers breast cancer biology from classification and risk factors through diagnosis and treatment, highlighting how the disease varies by subtype and between racial groups. The review examines both traditional factors like staging systems and molecular subtypes (Luminal A/B, Triple Negative, HER2-enriched) as well as emerging research on genetic mutations, epigenetic changes, and microbiome imbalances that may contribute to breast cancer development and progression. Recent evidence suggests that disruptions in the body’s microbial communities may play a role in breast cancer, with patterns potentially differing across populations, adding a new dimension to understanding racial disparities in breast cancer outcomes.
2024
Cancer Med
A mouse study found that exposure to bacterial toxins (lipopolysaccharides or LPS) during puberty—a critical period for breast development—caused lasting inflammation and changes in gene expression that increased breast cancer risk later in life. Researchers discovered that a prebiotic supplement derived from shiitake mushrooms (AHCC) could counteract these harmful effects by reducing inflammation, regulating immune signaling molecules, and blocking cancer-promoting gene activity in mammary tissue. The findings suggest that gut health and inflammation during puberty may influence long-term breast cancer risk, and that dietary interventions like prebiotics might offer a preventive strategy, though human studies are needed to confirm these results.
2023
Microbiol Spectr
A study of 117 postmenopausal African women found significant links between blood levels of estrogens (hormones associated with breast cancer risk) and the composition of bacteria in both the gut and mouth. Higher levels of certain estrogens were associated with greater diversity of gut bacteria, while specific estrogen byproducts were linked to differences in oral bacteria composition, including bacterial families known to help metabolize estrogens. These findings suggest that gut and oral bacteria may influence breast cancer risk by affecting how the body processes estrogens, though larger studies are needed to confirm how these relationships develop over time.
2023
Nutrients
A case-control study of 42 newly diagnosed, treatment-naïve breast cancer patients and 44 age-matched cancer-free controls at Oregon Health & Science University (2020-2021) found reduced gut microbial diversity in breast cancer patients and enrichment of three specific bacterial genera—Acidaminococcus, Tyzzerella, and Hungatella—in fecal samples from cases, with these genera associated with distinct dietary patterns including vegetables and dairy (Hungatella) and whole fruits (Acidaminococcus). Breast cancer patients also had significantly higher BMI and lower physical activity levels, and microbiome analysis revealed significant differences in composition between cases and controls using 16S rRNA sequencing. These findings highlight complex interactions between the gut microbiome, dietary habits (assessed via National Cancer Institute Diet History Questionnaire), lifestyle factors like weight management and physical activity, and breast cancer risk, suggesting the gut microbiome may serve as a source of biomarkers for breast cancer risk assessment, though larger studies are needed to establish causal relationships and validate these microbial signatures.
2023
Gut Microbes
A mouse study revealed that Vitamin D receptor (VDR) deficiency in the gut lining leads to bacterial imbalance (dysbiosis), increased intestinal permeability (“leaky gut”), and bacterial migration to breast tissue, significantly increasing breast tumor formation. Mice lacking intestinal VDR developed larger and more numerous breast tumors, with harmful bacteria like Streptococcus found in the tumor tissue, while beneficial bacteria that normally protect against cancer were depleted. However, treatment with butyrate (a beneficial bacterial byproduct) or the probiotic Lactobacillus plantarum reduced breast tumors by restoring gut barrier function and reducing inflammation, demonstrating a direct gut-breast axis. These findings suggest that maintaining gut health through adequate Vitamin D, beneficial bacteria, and a healthy microbiome may be a promising strategy for breast cancer prevention, though human studies are needed to confirm these results.
2023
Sci Total Environ
In a transgenic mouse model (MMTV-Erbb2) that naturally develops mammary tumors, mice given oral cadmium (3.6 mg/L in drinking water for 23 weeks) developed palpable tumors significantly earlier and showed accelerated tumor growth compared with unexposed controls. Cadmium exposure increased the proliferation marker Ki-67, enhanced focal necrosis and new blood vessel formation in mammary tumors, and triggered greater intratumoral glutamine metabolism. Notably, disrupting gut microbiota with antibiotics delayed tumor onset and reduced tumor weight, implicating gut-microbiome–mediated metabolic reprogramming in cadmium-driven mammary tumorigenesis.
2022
Int J Cancer
A study of 881 Ghanaian women found that lower diversity of bacteria in the mouth was associated with increased risk of both breast cancer and nonmalignant breast disease, with specific bacterial types like Porphyromonas and Fusobacterium being less common in breast cancer patients. The research also revealed that among women with breast cancer, the composition of oral bacteria was strongly linked to their gut bacteria composition, while this connection was weak in healthy women. These findings suggest that the oral microbiome—the community of bacteria living in the mouth—may play a role in breast cancer risk and could potentially serve as a marker for disease, though more research is needed to understand how these bacteria might influence cancer development.
2021
Breast
A systematic review of 22 studies found that breast skin harbors distinct bacterial communities, with imbalances in these bacteria—particularly certain Staphylococcus species—linked to breast cancer, metastases, inflammation, and implant complications. The research suggests bacteria can migrate from skin into underlying breast tissue through milk ducts, damaged skin barriers, or nipple fluid, potentially contributing to disease development. These findings indicate that breast skin bacteria may be a modifiable risk factor for breast diseases, opening possibilities for using probiotics, antimicrobials, or microbiome-based diagnostics as new tools for prevention, diagnosis, and treatment of breast conditions.
2020
Int J Mol Sci
The gut microbiome—trillions of bacteria living in the digestive tract—appears to influence breast cancer risk, treatment effectiveness, and likelihood of recurrence through its effects on metabolism, hormones, immune function, and brain signaling. While cancer treatments can disrupt the gut microbiome and contribute to negative side effects, research shows that the microbiome can be positively modified through diet, probiotic and prebiotic supplements, and exercise. This review synthesizes current evidence on the gut-breast cancer connection and highlights practical strategies for improving gut health that may lead to better treatment outcomes, fewer side effects, and improved overall wellbeing for breast cancer patients.
2020
Breast Cancer Res Treat
A pilot study of 37 breast cancer patients found that women with HER2-positive breast cancer (an aggressive subtype) had 12-23% lower gut bacterial diversity and different bacterial compositions compared to HER2-negative patients, with less Firmicutes and more Bacteroidetes bacteria. The research also revealed that women who started menstruating early (age 11 or younger) and those with higher body fat had lower gut bacterial diversity, suggesting links between gut microbiome composition and known breast cancer risk factors. While the study was small, these findings indicate that gut bacteria composition may be connected to both breast cancer characteristics and established risk factors, warranting larger studies to better understand these relationships and their potential implications for prevention and treatment.
2020
Cells
A comprehensive review reveals that imbalanced gut and body microbiomes are linked to nearly all established breast cancer risk factors—including obesity, aging, periodontal disease, alcohol intake, reproductive history, and elevated estrogen levels—suggesting that microbial dysbiosis may itself be an important independent risk factor. The altered bacteria can promote cancer through multiple mechanisms: producing harmful metabolic byproducts, changing how the body processes medications and environmental chemicals, disrupting immune system function, and affecting how well cancer treatments work. These findings suggest that maintaining a healthy microbiome through diet, lifestyle, or therapeutic interventions could potentially reduce breast cancer risk and improve treatment outcomes, representing a promising new frontier in breast cancer prevention and management.
2020
Pharmacol Res
A comprehensive review of 10 studies including over 3.7 million individuals found that people who had ever used oral antibiotics had an 18% increased risk of breast cancer, with the association varying by antibiotic type—penicillin, tetracycline, and nitrofuran antibiotics showed the strongest links. The relationship appeared complex and possibly non-linear, with data hinting at increased risk with moderate antibiotic use but potential protective effects after 35 or more prescriptions, though this finding requires careful interpretation due to study limitations. It remains unclear whether antibiotics directly cause breast cancer or whether the association reflects other factors like underlying infections, immune function changes, or disruption of the gut microbiome, highlighting the need for further research into the mechanisms behind this relationship.
2018
Curr Oncol Rep
Obesity is now recognized as a leading preventable cause of cancer, particularly postmenopausal estrogen receptor-positive breast cancer, and is associated with worse outcomes across all breast cancer subtypes. Multiple interconnected mechanisms link obesity to breast cancer, including elevated estrogen levels, altered hormone-like molecules from fat tissue (leptin and adiponectin), disrupted insulin signaling, changes in gut bacteria, and chronic inflammation throughout the body. Understanding these complex pathways could lead to new prevention and treatment strategies to reduce the growing burden of obesity-related breast cancers worldwide.
2025
Int J Cancer
The “estrobolome”—gut bacteria involved in processing estrogens and related compounds—has been theorized to influence breast cancer risk by affecting hormone levels, but a comprehensive review found limited and inconsistent evidence linking specific bacterial species to breast cancer. Only two bacteria (Escherichia coli and Roseburia inulinivorans) showed both functional relevance and differences between breast cancer patients and healthy controls, suggesting that either measurement methods need improvement or that broader ecological changes in the gut microbiome are more important than specific estrogen-processing bacteria. The review calls for future studies using advanced techniques like metabolomics and transcriptomics alongside microbiome sequencing to better understand whether and how gut bacteria influence breast cancer through hormone pathways, while accounting for lifestyle and clinical factors that may modify these relationships.
2024
BMC Cancer
A Mendelian randomization study using GWAS data from the MiBioGen consortium (18,340 samples across 24 global populations analyzing 211 gut bacterial taxa) and breast cancer data from FinnGen and Biobank Japan identified population-specific causal relationships between gut microbiota and breast cancer risk. In Europeans, Erysipelatoclostridium increased risk (OR = 1.21; 95% CI: 1.08-1.36) while Coriobacteriia/Coriobacteriales/Coriobacteriaceae decreased risk (OR = 0.76; 95% CI: 0.62-0.93); in East Asians, Eubacterium ruminantium increased risk (OR = 1.26; 95% CI: 1.06-1.50) while Porphyromonadaceae (OR = 0.30; 95% CI: 0.16-0.60) and Ruminococcaceae (OR = 0.67; 95% CI: 0.51-0.90) decreased risk, though the latter two had limited statistical power. These findings demonstrate that gut microbiota may causally influence breast cancer risk differently across populations, suggesting potential for developing targeted, ethnicity-appropriate prevention and treatment strategies based on microbiome modulation.
2023
Gut Microbes
Glyphosate, the active ingredient in Roundup herbicide, works by blocking a pathway that plants use to make certain amino acids—a pathway that humans don’t have—but this same pathway exists in gut bacteria, raising concerns about the herbicide’s effects on the human microbiome. Growing evidence suggests that Glyphosate exposure may disrupt the balance of beneficial bacteria in the gut, potentially inhibiting their growth or altering their function, which could have important health implications given the gut microbiome’s significant role in overall wellbeing. This review highlights the need for further research into how Glyphosate exposure affects gut bacteria composition and function, as disruptions to the microbiome have been linked to various health disorders.
2020
Sci Rep
A study comparing breast tissue from Black and White women with different breast cancer subtypes found distinct patterns of bacteria living in the tissue that varied by both race and cancer type. In Black women with triple-negative breast cancer (an aggressive subtype), tumors had lower bacterial diversity compared to surrounding normal tissue, while White women showed the opposite pattern with higher diversity in tumors. These findings suggest that the bacterial communities in breast tissue differ between racial groups and may play a role in the known disparities in breast cancer subtypes and outcomes, though more research is needed to understand how these bacteria influence cancer development.